Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus standard induction and consolidation chemotherapy in newly diagnosed FLT3-mutated AML
NL-OMON32771Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Midostaurin plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Overall survival. Started May 2008; status: recruiting.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON32771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32771.